Zanidatamab, a Dual HER2-Targeted Bispecific Antibody, in Patients With Unresectable Locally Advanced or Metastatic HER2-Positive Salivary Gland Cancer: A Combined Analysis of Early-Phase Studies
Although the sample size is small, these findings support the clinical benefit of zanidatamab treatment for HER2-positive SGC.
Authors
- Muralidhar Beeram
- Emanuele Loro (ORCID: https://orcid.org/0000-0002-0822-4514)
- Kay T. Yeung (ORCID: https://orcid.org/0000-0002-0013-7002)
- Kavita Shah (ORCID: https://orcid.org/0000-0002-0451-1305)
- Diana Shpektor
- Douglas S. Fuller (ORCID: https://orcid.org/0000-0002-2448-5896)
- T. Samuel Nached
- Keun-Wook Lee
- Toshihiko Doi
- Elena Elimova
- Do-Youn Oh
- Funda Meric-Bernstam
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- National Foundation for Cancer Research (US)
- New Generation University College (ET)
- Princess Margaret Cancer Centre (CA)
- Seoul National University Bundang Hospital (KR)
- Jazz Pharmaceuticals (United States) (US)
- South Texas Accelerated Research Therapeutics (US)
- Jazz Pharmaceuticals (Italy) (IT)
- National Cancer Center Hospital East (JP)
- Jazz Pharmaceuticals (France) (FR)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-03-23
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-4158
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00